Combines two Alzheimer’s-related blood biomarkers with APOE genotyping, which provides genetic-risk information.
Used in clinician-led assessment of cognitive impairment and may help inform discussions about genetic susceptibility and the risk of ARIA with certain anti-amyloid treatments.